Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07298473

Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

Led by Medtronic Cardiac Ablation Solutions · Updated on 2026-04-13

400

Participants Needed

30

Research Sites

103 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Conquer-AF is a prospective, multi-center, interventional, non-randomized clinical study that will enroll up to 400 subjects at up to 30 sites across the United States, Europe, and Australia. Subjects diagnosed with symptomatic recurrent paroxysmal or persistent atrial fibrillation after a single prior ablation procedure will be enrolled in this study. Each subject will undergo a study index redo ablation procedure using the Sphere-9 Catheter and Affera Ablation System and will be followed for 12 months. The expected total study duration (from time of first enrollment to the exit of last enrolled subject) is approximately 2 years.

CONDITIONS

Official Title

Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • History of a single atrial fibrillation ablation procedure for paroxysmal or persistent AF within 3 years prior to enrollment
  • Documented symptomatic AF, atrial tachycardia, or atrial flutter recurrence at least 90 days after the original ablation
  • Physician note indicating at least one symptomatic episode within 12 months before enrollment
  • At least one electrocardiographically documented episode within 12 months before enrollment
  • Adults aged 18 years or older on the day of enrollment
  • Willing and able to follow all study requirements and provide informed consent
Not Eligible

You will not qualify if you...

  • Continuous atrial fibrillation lasting 12 months or longer
  • Left atrial diameter greater than 55 mm (persistent AF) or 50 mm (paroxysmal AF), or specified volume limits if diameter not available
  • Previous left atrial interventions including appendage occlusion or septal closure devices
  • Planned left atrial appendage closure, cardiac transplant, or implant of pacemaker, defibrillator, or cardiac monitor during follow-up
  • More than one previous AF ablation procedure or any prior surgical ablation
  • Not on oral anticoagulation therapy for at least 3 weeks before ablation
  • Contraindication to or unwillingness to use systemic anticoagulation
  • Severe bleeding or clotting disorders
  • Presence of pacemakers, defibrillators, or pulmonary vein stents
  • Known pulmonary vein stenosis or hemidiaphragmatic paralysis
  • Prior valvular procedures or moderate to severe valve disease
  • Recent cardiac surgery, heart attack, or coronary procedures within 3 months
  • NYHA Class III or IV heart failure
  • Left ventricular ejection fraction 40% or less
  • Unstable angina
  • Severe lung disease or pulmonary hypertension requiring oxygen
  • Rheumatic heart disease or significant lung disease
  • Left atrial thrombus or active infection
  • Hypertrophic cardiomyopathy, amyloid heart disease, or atrial myxoma
  • Reversible causes of AF like uncontrolled hyperthyroidism or severe sleep apnea
  • Stroke or TIA within past 6 months
  • Carotid stenting or endarterectomy
  • Recent thromboembolic event or intracardiac thrombus
  • Body mass index over 40 kg/m2
  • Pregnancy, breastfeeding, or unreliable contraception
  • Life expectancy unlikely to complete 12 months follow-up
  • Participation in other unapproved clinical studies
  • Severe kidney failure or dialysis
  • Vascular access abnormalities or inferior vena cava filters
  • Known drug or alcohol dependency
  • Significant congenital or medical problems that affect study participation or integrity

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 30 locations

1

University of Alabama at Birmingham (UAB) Hospital

Birmingham, Alabama, United States, 35233

Not Yet Recruiting

2

Scripps Green Hospital

La Jolla, California, United States, 92037

Not Yet Recruiting

3

Cedars Sinai Medical Center

Los Angeles, California, United States, 90048-1804

Not Yet Recruiting

4

NCH Rooney Heart Institute

Naples, Florida, United States, 34102

Actively Recruiting

5

AdventHealth Cardiovascular Research Institute

Orlando, Florida, United States, 32803

Not Yet Recruiting

6

Piedmont Heart Institute

Atlanta, Georgia, United States, 30309

Not Yet Recruiting

7

Memorial Health University Medical Center

Savannah, Georgia, United States, 31404

Not Yet Recruiting

8

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114-2621

Actively Recruiting

9

Kansas City Heart Rhythm Institute (Midwest Heart and Vascular Specialist)

Kansas City, Missouri, United States, 64111

Not Yet Recruiting

10

Northwell Health Lenox Hill Hospital

New Hyde Park, New York, United States, 11040-1402

Not Yet Recruiting

11

NYU Langone Medical Center

New York, New York, United States, 10016-4972

Not Yet Recruiting

12

Montefiore Medical Center

The Bronx, New York, United States, 10467

Not Yet Recruiting

13

Cleveland Clinic Foundation

Cleveland, Ohio, United States, 44195

Not Yet Recruiting

14

OhioHealth Research and Innovation Institute (OHRI)

Columbus, Ohio, United States, 43214-3467

Not Yet Recruiting

15

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Not Yet Recruiting

16

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States, 15212-4756

Not Yet Recruiting

17

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232-0019

Not Yet Recruiting

18

Texas Cardiac Arrhythmia Research Foundation

Dallas, Texas, United States, 75226

Actively Recruiting

19

Texas Health Fort Worth

Fort Worth, Texas, United States, 76104

Not Yet Recruiting

20

Inova Fairfax Hospital

Falls Church, Virginia, United States, 22042

Not Yet Recruiting

21

Centra Medical Group Stroobants Cardiovascular Center

Lynchburg, Virginia, United States, 24501

Not Yet Recruiting

22

Sentara Norfolk General Hospital

Newport News, Virginia, United States, 23606-2981

Not Yet Recruiting

23

Westmead Hospital

Westmead, New South Wales, Australia, 2145

Not Yet Recruiting

24

Adelaide University

Adelaide, South Australia, Australia, 5000

Not Yet Recruiting

25

The Royal Melbourne Hospital

Parkville, Victoria, Australia, 3050

Actively Recruiting

26

Universitair Ziekenhuis Brussel

Brussels, Belgium, 1090

Not Yet Recruiting

27

IKEM - Institut Klinické a Experimentální Medicíny

Prague, Czechia, 140 21

Not Yet Recruiting

28

Motol and Homolka University Hospital

Prague, Czechia, 150 30

Not Yet Recruiting

29

Clinique Pasteur

Toulouse, France, 31076

Not Yet Recruiting

30

Inselspital - Universitätsspital Bern

Bern, Switzerland, 3010

Not Yet Recruiting

Loading map...

Research Team

R

Ryan S Radtke, Bachelors of Science- Biology

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here